Shigemura K et al. – Naftopidil 75 mg might show a better efficacy for lower urinary tract symptoms with benign prostatic hyperplasia in nocturia frequency than Tam 0.2 mg.Methods
- Seventy-seven patients with LUTS secondary to BPH were enrolled.
- Data were gathered from patients retrospectively: 41 patients who were prescribed Naf 75 mg for 4 weeks and 36 patients who were prescribed Tam 0.2 mg for 4 weeks, respectively.
- The efficacy criteria were improvement in LUTS International Prostate Symptom Score (IPSS) and quality of life (QOL) scores after dosing.
- Naf 75 mg significantly improved symptoms in all 11 categories (overall IPSS, incomplete emptying, voiding symptoms [Intermittency, poor flow and straining], storage symptoms [daytime frequency, urgency and nocturia frequency], QOL index, intermittency, poor flow, straining, daytime frequency, urgency, and nocturia frequency) (P < 0.05).
- Tam 0.2 mg significantly suppressed 10 of the 11 tested symptom categories except straining (P < 0.05).
- Comparison data of the two drugs tended to show Naf 75 mg had better efficacy on nocturia frequency than Tam 0.2 mg (P < 0.05).